Government of Canada receives first delivery of COVID-19 oral antiviral treatment

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Government of Canada receives first delivery of COVID-19 oral antiviral treatment

Canada NewsWire

GATINEAU, QC, Jan. 17, 2022 /CNW/ - Public Services and Procurement Canada

The Government of Canada is committed to protecting the health and safety of everyone in Canada from COVID‑19. This includes securing safe and effective treatments as they become available.

Today, the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has received an initial shipment of 30,400 treatment courses of Pfizer's COVID-19 oral antiviral treatment, PAXLOVIDTM, with 120,000 more expected to be delivered between now and the end of March. The treatment received Health Canada regulatory authorization earlier today.

Vaccination and public health measures remain the best way to protect the public against infection and severe disease. However, access to effective, easy-to-use treatments, such as the one produced by Pfizer, could be critical to reducing the severity of COVID-19 in people who become infected.

Distribution to provinces and territories will begin imminently. The Government of Canada is working closely with the provinces and territories to coordinate distribution of treatment courses across the country. The Public Health Agency of Canada met with provincial and territorial officials to discuss deployment based on a per capita basis with adjustments due to shipping requirements from Pfizer.

Canada has secured 1 million courses of the treatment. Delivery schedules are being finalized, with the intent of bringing additional treatment courses to Canada as quickly as possible.


"This announcement marks another important milestone in Canada's fight against COVID-19. We will always do what is necessary to protect the health and safety of everyone in Canada and ensure access to safe and effective treatments such as PAXLOVIDTM."

The Honourable Filomena Tassi
Minister of Public Services and Procurement

"We remain committed to using all the tools available to protect Canadians and manage challenges brought on by the Omicron wave. Access to easy-to-use treatments, such as PAXLOVIDTM, is critical in reducing the severity of COVID-19 in Canadians at high risk of progressing to serious illness, and in helping ease the burden on our healthcare system. This is yet another tool that we can use to fight COVID-19 along with vaccines, rapid tests and following all local public health guidelines."

The Honourable Jean-Yves Duclos
Minister of Health

Quick facts

  • Public Services and Procurement Canada and the Public Health Agency of Canada are working together to purchase and distribute COVID-19 vaccines, treatments and related supplies.
  • On January 17, 2021, Health Canada authorized the use of Pfizer's oral antiviral treatment, PAXLOVIDTM, to treat mild to moderate COVID-19 in non-hospitalized adults who are at high risk of progressing to serious illness, including hospitalization or death.
  • Canada also secured access to 500,000 courses of Merck's COVID-19 oral antiviral treatment, molnupiravir, with options for up to 500,000 more, pending Health Canada's authorization.

Associated links

Coronavirus disease (COVID-19): Canada's response
Supplying Canada's response to COVID-19
Government of Canada signs agreements for COVID-19 oral antiviral treatments
Drug and vaccine authorizations for COVID-19: List of applications received

Follow us on Twitter
Follow us on Facebook

SOURCE Public Services and Procurement Canada

Cision View original content:

Copyright CNW Group 2022

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).